Current Treatment Methods in Pancreatic Cancer and the Need for Improvement
DOI:
https://doi.org/10.47611/jsrhs.v13i4.8357Keywords:
pancreatic cancer, mRNA vaccines, immunotherapies, Whipple procedure, Stereotactic body radiation therapy (SBRT)Abstract
Pancreatic cancer, one of the deadliest cancers worldwide, necessitates improved therapeutics due to its low survival rate (12% in 5 years) and typically late-stage diagnosis [1]. This malignancy tends to present asymptomatically until advanced stages, leading to high rates of metastasis and limiting surgical options [2]. Genetic mutations in key genes like KRAS, CDKN2A, TP53, and SMAD4 are central to pancreatic cancer pathogenesis, driving uncontrolled cell proliferation and making treatment difficult [3]. Current treatment modalities include surgery, chemotherapy, radiation, and emerging immunotherapies. Surgery, particularly the Whipple procedure, offers the only potential cure but is applicable in just 15-20% of cases due to the late diagnosis [4]. Chemotherapy, though commonly used, offers limited long-term survival benefits [5]. Radiation therapy has seen advancements with techniques like stereotactic body radiation therapy (SBRT), which shows promise in reducing toxicity and improving outcomes [6]. Immunotherapy, particularly mRNA vaccines, has demonstrated potential in prolonging recurrence-free survival (>18 months), especially when combined with traditional therapies (13.4 months with surgical resection alone) [7]. Combinations of different treatments have been found to be effective. The challenge of early pancreatic cancer diagnosis mirrors the difficulty of disease management. Prophylactic immunotherapies, like vaccines, could offer a crucial breakthrough for prevention and recurrence reduction. As pancreatic cancer remains difficult to treat effectively, continued research and development in preventative and therapeutic strategies are essential to improving outcomes.
Downloads
References or Bibliography
Cancer of the Pancreas—Cancer Stat Facts. (n.d.). SEER. Retrieved July 8, 2024, from https://seer.cancer.gov/statfacts/html/pancreas.html
Why Is Pancreatic Cancer So Deadly and What Are the Treatment Options. (n.d.). Retrieved July 8, 2024, from https://www.medstarhealth.org/blog/pancreatic-cancer-deadly-treatment-options
KRAS gene: MedlinePlus Genetics. (n.d.). Retrieved July 8, 2024, from https://medlineplus.gov/genetics/gene/kras/
Artinyan, A., Soriano, P. A., Prendergast, C., Low, T., Ellenhorn, J. D. I., & Kim, J. (2008). The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB : The Official Journal of the International Hepato Pancreato Biliary Association, 10(5), 371–376. https://doi.org/10.1080/13651820802291233
Chemotherapy Change Improves Pancreatic Cancer Outcomes—NCI (nciglobal,ncienterprise). (2018, June 28). [cgvBlogPost]. https://www.cancer.gov/news-events/cancer-currents-blog/2018/pancreatic-cancer-chemotherapy-regimen-change
Burkoň, P., Trna, J., Slávik, M., Němeček, R., Kazda, T., Pospíšil, P., Dastych, M., Eid, M., Novotný, I., Procházka, T., & Vrzal, M. (2022). Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer—A Critical Review and Practical Consideration. Biomedicines, 10(10), 2480. https://doi.org/10.3390/biomedicines10102480
Huang, X., Zhang, G., Tang, T.-Y., Gao, X., & Liang, T.-B. (2022). Personalized pancreatic cancer therapy: From the perspective of mRNA vaccine. Military Medical Research, 9(1), 53. https://doi.org/10.1186/s40779-022-00416-w
Pancreas Functions, Location & Disease | Columbia Surgery. (n.d.). Retrieved July 8, 2024, from https://columbiasurgery.org/pancreas/pancreas-and-its-functions
What Is Cancer? - NCI (nciglobal,ncienterprise). (2007, September 17). [cgvArticle]. https://www.cancer.gov/about-cancer/understanding/what-is-cancer
How cancer can spread. (2014, October 29). Cancer Research UK. https://www.cancerresearchuk.org/about-cancer/what-is-cancer/how-cancer-can-spread
About Pancreatic Cancer | Penn Pancreatic Cancer Research Center | Perelman School of Medicine at the University of Pennsylvania. (n.d.). Retrieved July 8, 2024, from https://www.med.upenn.edu/pcrc/aboutpancreaticcancer.html
Prostate Cancer Prognosis. (2023, November 6). https://www.hopkinsmedicine.org/health/conditions-and-diseases/prostate-cancer/prostate-cancer-prognosis
Survival Rates for Breast Cancer. (n.d.). Retrieved July 8, 2024, from https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016). Pancreatic cancer. The Lancet, 388(10039), 73–85. https://doi.org/10.1016/S0140-6736(16)00141-0
Zhang, Z., Zhang, H., Liao, X., & Tsai, H. (2023). KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1147676
Kimura, H., Klein, A. P., Hruban, R. H., & Roberts, N. J. (2021). The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer. Pancreas, 50(8), 1123–1130. https://doi.org/10.1097/MPA.0000000000001888
Roberts, N. J., Norris, A. L., Petersen, G. M., Bondy, M. L., Brand, R., Gallinger, S., Kurtz, R. C., Olson, S. H., Rustgi, A. K., Schwartz, A. G., Stoffel, E., Syngal, S., Zogopoulos, G., Ali, S. Z., Axilbund, J., Chaffee, K. G., Chen, Y.-C., Cote, M. L., Childs, E. J., … Klein, A. P. (2016). Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discovery, 6(2), 166–175. https://doi.org/10.1158/2159-8290.CD-15-0402
McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M. (2022). Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. Cells, 11(14), 2155. https://doi.org/10.3390/cells11142155
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., Frame, M. C., Evans, T. R. J., & Sansom, O. J. (2010). Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences, 107(1), 246–251. https://doi.org/10.1073/pnas.0908428107
Racu, M.-L., Bernardi, D., Chaouche, A., Zindy, E., Navez, J., Loi, P., Maris, C., Closset, J., Van Laethem, J.-L., Decaestecker, C., Salmon, I., & D’Haene, N. (2023). SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy. Cancers, 15(15), 3765. https://doi.org/10.3390/cancers15153765
Pancreatic Cancer Treatment—NCI (nciglobal,ncienterprise). (2024, April 26). [pdqCancerInfoSummary]. https://www.cancer.gov/types/pancreatic/patient/pancreatic-treatment-pdq
Prognosis if you can have surgery. (n.d.). Pancreatic Cancer UK. Retrieved August 5, 2024, from https://www.pancreaticcancer.org.uk/information/just-diagnosed-with-pancreatic-cancer/if-you-can-have-surgery-to-remove-the-cancer-early-pancreatic-cancer/prognosis-if-you-can-have-surgery/
Sohn, T. A., Yeo, C. J., Cameron, J. L., Koniaris, L., Kaushal, S., Abrams, R. A., Sauter, P. K., Coleman, J., Hruban, R. H., & Lillemoe, K. D. (2000). Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract, 4(6), 567–579. https://doi.org/10.1016/s1091-255x(00)80105-5
Types of surgery for pancreatic cancer. (n.d.). Retrieved July 15, 2024, from https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/treatment/surgery/which-surgery
Tran, K. T. C., Smeenk, H. G., van Eijck, C. H. J., Kazemier, G., Hop, W. C., Greve, J. W. G., Terpstra, O. T., Zijlstra, J. A., Klinkert, P., & Jeekel, H. (2004). Pylorus Preserving Pancreaticoduodenectomy Versus Standard Whipple Procedure. Annals of Surgery, 240(5), 738–745. https://doi.org/10.1097/01.sla.0000143248.71964.29
Gastroparesis. (n.d.). Yale Medicine. Retrieved August 5, 2024, from https://www.yalemedicine.org/conditions/gastroparesis
Whipple procedure—Mayo Clinic. (n.d.). Retrieved July 31, 2024, from https://www.mayoclinic.org/tests-procedures/whipple-procedure/about/pac-20385054
DeMarco, C. (n.d.). Whipple procedure: 9 things to know. MD Anderson Cancer Center. Retrieved July 31, 2024, from https://www.mdanderson.org/cancerwise/whipple-procedure-and-pancreatic-cancer-treatment-9-things-to-know.h00-159459267.html
Whipple Procedure: What Is It, Treatment & Recovery. (n.d.). Cleveland Clinic. Retrieved July 31, 2024, from https://my.clevelandclinic.org/health/treatments/21650-whipple-procedure-pancreaticoduodenectomy
10-year survival rate after whipple surgery—Seena Magowitz Foundation. (n.d.). Retrieved July 31, 2024, from https://seenamagowitzfoundation.org/whipple-operation/
Pancreatectomy Surgery: Procedure, Types & Definition. (n.d.). Cleveland Clinic. Retrieved July 16, 2024, from https://my.clevelandclinic.org/health/treatments/23134-pancreatectomy-surgery-removal-pancreas
Pancreatectomy (Removal of Pancreas). (n.d.). UPMC Hillman Cancer Center. Retrieved July 31, 2024, from https://hillman.upmc.com/cancer-care/pancreatic/treatment/surgery/pancreatectomy
Loos, M., Mack, C. E., Xu, A. T. L., Hassenpflug, M., Hinz, U., Mehrabi, A., Berchtold, C., Schneider, M., Al-Saeedi, M., Roth, S., Hackert, T., & Büchler, M. W. (2024). Distal Pancreatectomy: Extent of Resection Determines Surgical Risk Categories. Annals of Surgery, 279(3), 479. https://doi.org/10.1097/SLA.0000000000005935
Karpoff, H. M., Klimstra, D. S., Brennan, M. F., & Conlon, K. C. (2001). Results of Total Pancreatectomy for Adenocarcinoma of the Pancreas. Archives of Surgery, 136(1), 44–47. https://doi.org/10.1001/archsurg.136.1.44
Maggino, L., Malleo, G., Marchegiani, G., Viviani, E., Nessi, C., Ciprani, D., Esposito, A., Landoni, L., Casetti, L., Tuveri, M., Paiella, S., Casciani, F., Sereni, E., Binco, A., Bonamini, D., Secchettin, E., Auriemma, A., Merz, V., Simionato, F., … Salvia, R. (2019). Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 154(10), 932–942. https://doi.org/10.1001/jamasurg.2019.2277
Chemotherapy for Pancreatic Cancer. (n.d.). Retrieved July 31, 2024, from https://www.cancer.org/cancer/types/pancreatic-cancer/treating/chemotherapy.html
Springfeld, C., Jäger, D., Büchler, M. W., Strobel, O., Hackert, T., Palmer, D. H., & Neoptolemos, J. P. (2019). Chemotherapy for pancreatic cancer. La Presse Médicale, 48(3, Part 2), e159–e174. https://doi.org/10.1016/j.lpm.2019.02.025
Ye, X., Yu, Y., Zheng, X., & Ma, H. (2024). Clinical immunotherapy in pancreatic cancer. Cancer Immunology, Immunotherapy, 73(4), 64. https://doi.org/10.1007/s00262-024-03632-6
What are mRNA vaccines and how do they work?: MedlinePlus Genetics. (n.d.). Retrieved August 19, 2024, from https://medlineplus.gov/genetics/understanding/therapy/mrnavaccines/
Nishimoto, A. (2022). Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World Journal of Gastroenterology, 28(28), 3637–3643. https://doi.org/10.3748/wjg.v28.i28.3637
Heumann, T., Judkins, C., Li, K., Lim, S. J., Hoare, J., Parkinson, R., Cao, H., Zhang, T., Gai, J., Celiker, B., Zhu, Q., McPhaul, T., Durham, J., Purtell, K., Klein, R., Laheru, D., De Jesus-Acosta, A., Le, D. T., Narang, A., … Zheng, L. (2023). A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nature Communications, 14, 3650. https://doi.org/10.1038/s41467-023-39196-9
Published
How to Cite
Issue
Section
Copyright (c) 2024 Sriram Banigallapati
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
